About: Nouveautés thérapeutiques sur le SDRA

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Nouveautés thérapeutiques sur le SDRA Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Nouveautés thérapeutiques sur le SDRA
Creator	Dreyfuss, · Gaudry, S Ricard, J.-D
topic	covid:a7f317efb9616ae6244673f931f99707634de561#this
Source	PMC
abstract	Treatment of acute respiratory distress syndrome (ARDS) has been subject to many researches, sometimes leading to intense controversy. New findings in this field are varied. Effects on prognosis of commonly used treatments for ARDS have recently been investigated. Consistently, prone position, previously known to improve oxygenation without effect on mortality, has been shown to improve survival of the most severely hypoxemic patients. Administration of neuromuscular blocking agents in the acute phase of ARDS has been also shown to be beneficial on survival. In contrast, the exact place of extracorporeal membrane oxygenation (ECMO) in ARDS management remains to be defined despite data suggesting its possible efficiency. In addition, a new era of research has emerged with the advent of cell therapy. Mesenchymal stem cells are able to both promote alveolar epithelium repair and prevent infections. Their efficacy in animal models of ARDS still needs to be confirmed by clinical trials. Finally, other promising therapies including beta-2 adrenergic agonists and omega-3 fatty acids have shown significant limitations in large clinical studies on ARDS.
has issue date	2012-11-24(xsd:dateTime)
bibo:doi	10.1007/s13546-012-0566-6
bibo:pmid	32288733
has license	no-cc
sha1sum (hex)	a7f317efb9616ae6244673f931f99707634de561
schema:url	https://doi.org/10.1007/s13546-012-0566-6
resource representing a document's title	Nouveautés thérapeutiques sur le SDRA
has PubMed Central identifier	PMC7117833
has PubMed identifier	32288733
schema:publication	Reanimation
resource representing a document's body	covid:a7f317efb9616ae6244673f931f99707634de561#body_text
is http://vocab.deri.ie/void#inDataset of	https://covidontheweb.inria.fr:4443/about/id/http/ns.inria.fr/covid19/a7f317efb9616ae6244673f931f99707634de561
is schema:about of	named entity 'survie' named entity 'par' named entity 'survie' named entity 'Par' named entity 'therapeutic' named entity 'SYNDROME DE' named entity 'EST' named entity 'VENTRAL' named entity 'POSSIBLE' named entity 'RICHE' named entity 'PLACE' named entity 'DES' named entity 'PRISE EN CHARGE' named entity 'dans' named entity 'qui' named entity 'La place' named entity 'therapeutic strategies' named entity 'ARDS' named entity 'dont' named entity 'agression' named entity 'H1N1' named entity 'appliqué' named entity 'paracrine' named entity 'objectifs' named entity 'ECMO' named entity 'permet' named entity 'salbutamol' named entity 'avantages' named entity 'ECMO' named entity 'cytokines' named entity 'monocytes' named entity 'cytokines' named entity 'cette' named entity 'cisatracurium' named entity 'phase II' named entity 'ECMO' named entity 'digestif' named entity 'salbutamol' named entity 'Keratinocyte growth factor' named entity 'Intensive Care Medicine' named entity 'acute lung injury' named entity 'ECMO' named entity 'ECMO' named entity 'parenchyme' named entity 'ECMO' named entity 'le point' named entity 'sepsis' named entity 'Kcal' named entity 'salbutamol' named entity 'PaO2/FiO2' named entity 'H1N1' named entity 'Odds ratio' named entity 'BALTI' named entity 'ECMO' named entity 'ECMO' named entity 'permis' named entity 'surfactant' named entity 'EPA' named entity 'apports' named entity 'La stratégie' named entity 'dont' named entity 'la conception' named entity 'ECMO' named entity 'permet' named entity 'mois' named entity 'mmHg' named entity 'salbutamol' named entity 'permis' named entity 'cytokines' named entity 'permet' named entity 'phagocytose' named entity 'anticoagulation' named entity 'BALTI' named entity 'dont' named entity 'enteral feeding' named entity 'apports' named entity 'permet'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software